抗血管生成治疗在恶性胸腔积液中的应用进展
Progress of Anti-angiogenic Therapies on Malignant Pleural Effusions
-
摘要: 恶性胸腔积液（malignant pleural effusions, MPE）是晚期肿瘤的常见并发症，肺癌和恶性胸膜间皮瘤（malignant pleural mesothelioma, MPM）是MPE最常见的病因。MPE的治疗原则是在针对病因的全身治疗的基础上对胸腔进行局部治疗。血管内皮生长因子（vascular endothelial growth factor, VEGF）在MPE形成中的多个环节起着关键作用。贝伐珠单抗能抑制VEGF的活性，减少MPE的形成，改善患者预后。本综述系统回顾了贝伐珠单抗及其他抗血管生成药物在非小细胞肺癌（non-small cell lung cancer, NSCLC）和MPM相关MPE中的研究进展，阐述了不同抗血管生成药物对MPE的临床疗效和安全性。Abstract: Malignant pleural effusion(MPE) is a common complication of advanced tumors. Lung cancer and malignant pleural mesothelioma(MPM) are the most common causes of MPE. The principle of MPE treatment is to treat the thoracic cavity locally on the basis of etiological systemic treatment. Vascular endothelial growth factor(VEGF) plays a key role in the formation of MPE. Bevacizumab can inhibit the activity of VEGF, reduce the formation of MPE and improve the prognosis. This article systematically reviews the research progress of bevacizumab and other anti-angiogenic drugs on MPE caused by NSCLC and MPM, and illustrates the clinical efficacy and safety of different anti-angiogenic drugs on MPE.
下载:
